PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL VALSARTAN HYBRID COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT

Provided is a pharmaceutical composition comprising a sacubitril valsartan hybrid compound or a pharmaceutically acceptable salt thereof as an active ingredient wherein sodium hydrogen carbonate is contained as a dissolution controller. Sodium hydrogen carbonate is contained in an amount of 10wt% to...

Full description

Saved in:
Bibliographic Details
Main Authors KIM, Moo Sung, OH, Jin Seob, KIM, Yong Han, KIM, Sang Yeop, LEE, Il Seung, KIM, Jin Sung, HWANG, Yong Youn, SON, Hyung Min
Format Patent
LanguageEnglish
French
Korean
Published 30.06.2022
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Provided is a pharmaceutical composition comprising a sacubitril valsartan hybrid compound or a pharmaceutically acceptable salt thereof as an active ingredient wherein sodium hydrogen carbonate is contained as a dissolution controller. Sodium hydrogen carbonate is contained in an amount of 10wt% to 40wt% on the basis of the total weight of the composition, whereby the dissolution rate is improved. L'invention concerne une composition pharmaceutique comprenant un composé hybride de sacubitril valsartan ou un sel pharmaceutiquement acceptable associé en tant que principe actif, le carbonate d'hydrogène de sodium étant contenu en tant que régulateur de dissolution. Le carbonate d'hydrogène de sodium est contenu dans une quantité de 10 % en poids à 40 % en poids sur la base du poids total de la composition, ce par quoi le taux de dissolution est amélioré. 사쿠비트릴 발사르탄 하이브리드 화합물 또는 이의 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물에 있어서 용출조절제로서 탄산수소나트륨을 포함하는 것을 특징으로 하는 약제학적 조성물이 제공된다. 탄산수소나트륨은 조성물 총 중량 당 10중량% 내지 40중량%로 포함되고 이에 의하여 용출률이 개선된다.
Bibliography:Application Number: WO2021KR19670